APA (7th ed.) Citation

Zolopa, A. R., Berger, D. S., Lampiris, H., Zhong, L., Chuck, S. L., Enejosa, J. V., . . . Cheng, A. K. (2010). Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial. The Journal of infectious diseases, 201(6), 814-822. https://doi.org/10.1086/650698

Chicago Style (17th ed.) Citation

Zolopa, Andrew R., Daniel S. Berger, Harry Lampiris, Lijie Zhong, Steven L. Chuck, Jeffrey V. Enejosa, Brian P. Kearney, and Andrew K. Cheng. "Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, Against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial." The Journal of Infectious Diseases 201, no. 6 (2010): 814-822. https://doi.org/10.1086/650698.

MLA (9th ed.) Citation

Zolopa, Andrew R., et al. "Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, Against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial." The Journal of Infectious Diseases, vol. 201, no. 6, 2010, pp. 814-822, https://doi.org/10.1086/650698.